Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study

[1]  K. Schmiegelow,et al.  Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Schmiegelow,et al.  Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy , 2018, Cancer Chemotherapy and Pharmacology.

[3]  O. Mäkitie,et al.  Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia , 2018, Pediatric blood & cancer.

[4]  K. Schmiegelow,et al.  Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia , 2017, Haematologica.

[5]  A. Borkhardt,et al.  Osteonecrosis in children with acute lymphoblastic leukemia , 2016, Haematologica.

[6]  L. Silverman,et al.  Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. , 2016, The Lancet. Oncology.

[7]  Melissa A. Basford,et al.  Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. , 2015, Blood.

[8]  J. Downing,et al.  Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Schmiegelow,et al.  Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia: Clinical Facts and Fiction , 2014, Journal of pediatric hematology/oncology.

[10]  P. Auquier,et al.  Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood , 2013, Haematologica.

[11]  T. Luider,et al.  Measuring methotrexate polyglutamates in red blood cells: a new LC-MS/MS-based method , 2013, Analytical and Bioanalytical Chemistry.

[12]  H. Sather,et al.  Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. , 2012, The Lancet. Oncology.

[13]  K. Schmiegelow,et al.  Liquid chromatography-tandem mass spectrometry quantification of 6-thioguanine in DNA using endogenous guanine as internal standard. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[14]  A. Vora.  Management of osteonecrosis in children and young adults with acute lymphoblastic leukaemia , 2011, British journal of haematology.

[15]  M. Relling,et al.  Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. , 2010, Blood.

[16]  B. Kamen.  Serendipity-methotrexate and 6-mercaptopurine for continuation therapy for patients with acute lymphoblastic leukemia: the leukemic stem cell and beyond? , 2009, Journal of pediatric hematology/oncology.

[17]  R. Barr,et al.  Osteonecrosis in children and adolescents with cancer - an adverse effect of systemic therapy. , 2007, European journal of cancer.

[18]  V. Armstrong,et al.  Determination of thiopurine methyltransferase activity in isolated human erythrocytes does not reflect putative in vivo enzyme inhibition by sulfasalazine. , 2004, Clinical chemistry.

[19]  K. Schmiegelow,et al.  Complying with the European Clinical Trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial. , 2014, European journal of cancer.

[20]  P. Karran,et al.  Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer , 2008, Nature Reviews Cancer.